Progress and Pitfalls of Bacteriophage Therapy in Critical Care: A Concise Definitive Review

Valente, Luca; Prazák, J; Que, Yok-Ai; Cameron, David R.

doi:10.1097/cce.0000000000000351

Cited by 15 publications

(12 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite its promise, the re-emergence of phase therapy is still in its relative infancy. Therefore, implementation is hindered by a lack of information regarding their efficacy or guidelines for their use or formulation [93][94][95]. Nevertheless, it could be an important adjunct for treating infections in the future.…”

Section: Phage Therapymentioning

confidence: 99%

Infection and Burn Injury

Kelly

Oliver

Carney

et al. 2022

EBJ

View full text Add to dashboard Cite

Burn injury is debilitating and among one of the most frequently occurring traumas. Critical care improvements have allowed for increasingly positive outcomes. However, infection, whether it be localized to the site of the wound or systemic in nature, remains a serious cause of morbidity and mortality. Immune suppression predisposes the burn population to the development of invasive infections; and this along with the possibility of inhalation injury puts them at a significant risk for mortality. Emerging multi-drug-resistant pathogens, including Staphylococcus aureus, Enterococcus, Pseudomonas, Acinetobacter, Enterobacter, and yeast spp., continue to complicate clinical care measures, requiring innovative therapies and antimicrobial treatment. Close monitoring of antimicrobial regimens, strict decontamination procedures, early burn eschar removal, adequate wound closure, proper nutritional maintenance, and management of shock and resuscitation all play a significant role in mitigating infection. Novel antimicrobial therapies such as ultraviolet light, cold plasma and topical antiseptics must continue to evolve in order to lower the burden of infection in burn.

show abstract

Section: Phage Therapymentioning

confidence: 99%

Infection and Burn Injury

Kelly

Oliver

Carney

et al. 2022

EBJ

View full text Add to dashboard Cite

show abstract

“…It is likely, particularly in critical care situations, that phage therapy will be administered adjunct to antibiotics [ 5 , 9 ]. The efficacy of phage therapy in animal models has now been tested extensively, however, only few studies have directly compared the efficacy of phages and antibiotics or assessed the efficacy of antibiotic-phage combinations in vivo.…”

Section: Main Textmentioning

confidence: 99%

“…Phages were as effective as antibiotics (the glycopeptide teicoplanin) when applied intravenously (IV), each rescuing about half of the animals from severe pneumonia [ 2 ]. An ongoing challenge for phage therapy moving forward is the identification and exploitation of phage-antibiotic synergies [ 5 ]; however, in the rat VAP model, the IV phage-antibiotic combination did not synergize and still half of the animals treated with the combination succumbed to the infection [ 2 ]. To determine if altering pharmacokinetic/pharmacodynamic (PK/PD) parameters could improve the efficacy of phage therapy, phages were nebulized and administered directly to the lungs of MRSA infected rats (‘aerophages’).…”

Section: Introductionmentioning

confidence: 99%

Searching for synergy: combining systemic daptomycin treatment with localised phage therapy for the treatment of experimental pneumonia due to MRSA

et al. 2021

Self Cite

View full text Add to dashboard Cite

Objective Bacteriophages (or phages) are viruses which infect and lyse bacteria. The therapeutic use of phages (phage therapy) has regained attention in the last decades as an alternative strategy to treat infections caused by antimicrobial-resistant bacteria. In clinical settings it is most likely that phages are administered adjunct to antibiotics. For successful phage therapy it is therefore crucial to investigate different phage-antibiotic combinations in vivo. This study aimed to elucidate the combinatorial effects of systemic daptomycin and nebulised bacteriophages for the treatment of experimental pneumonia due to methicillin-resistant Staphylococcus aureus (MRSA). Results Using a rat model of ventilator-associated pneumonia caused by MRSA, the simultaneous application of intravenous daptomycin and nebulised phages was not superior to aerophage therapy alone at improving animal survival (55% vs. 50%), or reducing bacterial burdens in the lungs, or spleen. Thus, this combination does not seem to be of benefit for use in patients with MRSA pneumonia.

show abstract

“…Many new therapies, such as those utilizing nanoparticles, phages, and protic ionic liquids, are being developed [ 7 , 8 , 9 , 10 , 11 ]. However, these technologies are still immature and have not been effectively used clinically [ 12 , 13 , 14 ]. At present, chemosynthesized antibacterial agents still play an indispensable role in clinical practice.…”

Section: Introductionmentioning

confidence: 99%

Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives

et al. 2022

View full text Add to dashboard Cite

In this study, a series of 3-(3-pyridyl)-oxazolidone-5-methyl ester derivatives was synthesized and characterized by 1H NMR, 13C NMR, and LC-MS. The conducted screening antibacterial studies of the new 3-(3-pyridyl)-oxazolidone-5-methyl ester derivatives established that the methyl sulfonic acid esters have broad activity spectrum towards Staphylococcus aureus, Streptococcus pneumoniae, Bacillus subtilis and Staphylococcus epidermidis. Among them, compound 12e has the most potent activity, with an MIC of 16 μg/mL against B.subtilis, and could reduce the instantaneous growth rate of bacteria. Furthermore, molecular docking studies were also simulated for compound 12e to predict the specific binding mode of this compound. In addition, anthelmintic activity of these compounds was also evaluated against adult Indian earthworms (Pheretima posthuman). The results showed that compound 11b had the best effect. These results above can provide experimental reference for the development of novel antibacterial and anthelmintic drugs.

show abstract

Progress and Pitfalls of Bacteriophage Therapy in Critical Care: A Concise Definitive Review

Abstract: Supplemental Digital Content is available in the text.

Cited by 15 publications

References 59 publications

Infection and Burn Injury

Infection and Burn Injury

Searching for synergy: combining systemic daptomycin treatment with localised phage therapy for the treatment of experimental pneumonia due to MRSA

Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives

Contact Info

Product

Resources

About